Entheon Biomedical Corp.

CNSX:ENBI Stock Report

Market Cap: CA$1.5m

Entheon Biomedical Past Earnings Performance

Past criteria checks 0/6

Entheon Biomedical has been growing earnings at an average annual rate of 46.4%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 49.1% per year.

Key information

46.4%

Earnings growth rate

64.7%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth rate49.1%
Return on equity-134.3%
Net Marginn/a
Last Earnings Update31 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Entheon Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:ENBI Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Aug 240000
31 May 240000
29 Feb 240000
30 Nov 230010
31 Aug 230010
31 May 230010
28 Feb 230-121
30 Nov 220-231
31 Aug 220-341
31 May 220-541
28 Feb 220-751
30 Nov 210-871
31 Aug 210-1061
31 May 210-951
28 Feb 210-731
30 Nov 200-410

Quality Earnings: ENBI is currently unprofitable.

Growing Profit Margin: ENBI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ENBI is unprofitable, but has reduced losses over the past 5 years at a rate of 46.4% per year.

Accelerating Growth: Unable to compare ENBI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENBI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: ENBI has a negative Return on Equity (-134.29%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:54
End of Day Share Price 2024/12/17 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Entheon Biomedical Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution